Logotype for Genomma Lab Internacional S.A.B. de C.V.

Genomma Lab Internacional (LABB) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Genomma Lab Internacional S.A.B. de C.V.

Q3 2026 earnings summary

30 Oct, 2026

Executive summary

  • Q3 net sales rose 1.3% YoY to MXN 4,497.6m as Latin America growth and Mexico’s continued recovery offset a steep U.S. decline.

  • Mexico sell-out returned to growth and market share held or improved across business units; new products supported sell-out gains among customers carrying them.

  • Net income increased 18.6%, supported by lower financing costs and a favorable, non-recurring FX result; promotional and commercial investment pressured margins.

Financial highlights

  • Q3 net sales were MXN 4,497.6m, up 1.3% YoY; gross profit fell 2.6% to MXN 2,762.1m and gross margin declined to 61.4% from 63.9%.

  • Operating income fell 10.8% to MXN 863.6m; EBITDA declined 10.3% to MXN 944.9m, with margin at 21.0% versus 23.7%.

  • Net income rose 18.6% to MXN 514.9m; EPS increased 18.6% to MXN 0.51.

  • 9M net sales declined 3.2% to MXN 13,085.3m and EBITDA fell 11.0% to MXN 2,859.8m, while net income rose 7.5% to MXN 1,384.1m.

  • Excluding IAS 29 and IAS 21 effects, Q3 net sales declined 6.2%, EBITDA fell 18.8%, and net income increased 20.2% YoY.

Outlook and guidance

  • Q4 2026 cash conversion cycle expected to decline to ~140 days as Mexican winter inventory sells through and Argentina’s non-cash accounting effect normalizes.

  • Brazil sell-in expected to normalize in Q1 2027 after customer inventory reductions ahead of the consumption tax reform.

  • U.S. recovery expected to be gradual; commercial footprint and distribution model are being realigned to stabilize performance.

  • Q4 2026 and Q1 2027 Cough & Cold launches planned; December 3 Investor Day in New York to present strategy, operating model, execution commitments, and an AI platform.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Genomma Lab Internacional